Abstract
The active form of the serine/threonine kinase cRaf-1 is upregulated postmortem in the brains of Alzheimers disease (AD) patients and in transgenic mouse models of AD pathology. The persistent activation of cRaf-1 can activate the proinflammatory factor NFκB and consequently, upregulate the expression of several of its downstream factors such as the amyloid precursor protein (APP), Cox-2 and iNOS. These factors have been found upregulated in numerous neurodegenerative conditions including AD, epilepsy, brain trauma, and psychological stress. The Raf kinase inhibitors, GW5074 and ZM336372, are neuroprotective against many different neurotoxic insults in vitro, including the A.. peptide, glutamate and glutathione depletion. Recently, we have reported that the multikinase and potent Raf inhibitor sorafenib reversed memory impairment and reduced the expression of APP, Cox-2, and iNOS in the brain of the transgenic mouse model of AD, APPswe. Similar improvement of behavioral outcome was attained after acute treatment with GW5074 in a mouse model of Huntingtons disease. Several Raf inhibitors have been developed to treat aggressive forms of cancer showing an upregulation of Raf kinases. These Raf inhibitors offer a great promise as therapeutic tools against neurological disorders. The negative and positive aspects of these inhibitors as anti-neurodegenerative agents are discussed.
Keywords: GW5074, sorafenib, Cox-2, iNOS, NFκB, neurodegeneration
CNS & Neurological Disorders - Drug Targets
Title: Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
Volume: 9 Issue: 1
Author(s): Sarah Burgess and Valentina Echeverria
Affiliation:
Keywords: GW5074, sorafenib, Cox-2, iNOS, NFκB, neurodegeneration
Abstract: The active form of the serine/threonine kinase cRaf-1 is upregulated postmortem in the brains of Alzheimers disease (AD) patients and in transgenic mouse models of AD pathology. The persistent activation of cRaf-1 can activate the proinflammatory factor NFκB and consequently, upregulate the expression of several of its downstream factors such as the amyloid precursor protein (APP), Cox-2 and iNOS. These factors have been found upregulated in numerous neurodegenerative conditions including AD, epilepsy, brain trauma, and psychological stress. The Raf kinase inhibitors, GW5074 and ZM336372, are neuroprotective against many different neurotoxic insults in vitro, including the A.. peptide, glutamate and glutathione depletion. Recently, we have reported that the multikinase and potent Raf inhibitor sorafenib reversed memory impairment and reduced the expression of APP, Cox-2, and iNOS in the brain of the transgenic mouse model of AD, APPswe. Similar improvement of behavioral outcome was attained after acute treatment with GW5074 in a mouse model of Huntingtons disease. Several Raf inhibitors have been developed to treat aggressive forms of cancer showing an upregulation of Raf kinases. These Raf inhibitors offer a great promise as therapeutic tools against neurological disorders. The negative and positive aspects of these inhibitors as anti-neurodegenerative agents are discussed.
Export Options
About this article
Cite this article as:
Burgess Sarah and Echeverria Valentina, Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases, CNS & Neurological Disorders - Drug Targets 2010; 9 (1) . https://dx.doi.org/10.2174/187152710790966632
DOI https://dx.doi.org/10.2174/187152710790966632 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Caring for Children with Medical Complexity: Definitions, Challenges and Solutions
Current Pediatric Reviews Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Disruption of Glutamate-Glutamine-GABA Cycle Significantly Impacts on Suicidal Behaviour: Survey of the Literature and Own Findings on Glutamine Synthetase.
CNS & Neurological Disorders - Drug Targets Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells
CNS & Neurological Disorders - Drug Targets Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology Progress and Outlooks in a Genetic Absence Epilepsy Model (WAG/Rij)
Current Medicinal Chemistry Neurosteroids and Sporadic Alzheimers Disease
Current Alzheimer Research Experimental Treatment Options in Absence Epilepsy
Current Pharmaceutical Design One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Inflammasome and Atherogenesis
Current Pharmaceutical Design Is There a Relationship Between Sweet Taste and Seizures? Anticonvulsant and Proconvulsant Effects of Non-Nutritive Sweeteners
Combinatorial Chemistry & High Throughput Screening Growing up with Midazolam in the Neonatal and Pediatric Intensive Care
Current Drug Metabolism Physiological and Pharmacological Insights into the Role of Ionic Channels in Cardiac Pacemaker Activity
Cardiovascular & Hematological Disorders-Drug Targets Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters